Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivolumab) of a relapsed classic Hodgkin lymphoma (HL) and was diagnosed post-mortem. The patient died of the progressive RIS that was misleadingly assumed to be a resistant HL based on the positive PET/CT scan. Repetitive tumor biopsies are warranted in cases of aggressive and multi-drug resistant HL to validate imaging findings, ensure correct diagnosis and avoid overtreatment.
References
1.
Altaf S, Enders F, Jeavons E, Krailo M, Barkauskas D, Meyers P
. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013; 60(12):2042-6.
DOI: 10.1002/pbc.24580.
View
2.
Hodgson D, Gilbert E, Dores G, Schonfeld S, Lynch C, Storm H
. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25(12):1489-97.
DOI: 10.1200/JCO.2006.09.0936.
View
3.
Kasamon Y, De Claro R, Wang Y, Shen Y, Farrell A, Pazdur R
. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist. 2017; 22(5):585-591.
PMC: 5423515.
DOI: 10.1634/theoncologist.2017-0004.
View
4.
Walden M, Murphey M, Vidal J
. Incidental enchondromas of the knee. AJR Am J Roentgenol. 2008; 190(6):1611-5.
DOI: 10.2214/AJR.07.2796.
View
5.
Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N
. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000; 85(9):3227-32.
DOI: 10.1210/jcem.85.9.6808.
View